Incidence of Intraocular Pressure Elevation following Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration

Gustavo Msm Reis; John Grigg; Brian Chua; Anne Lee; Ridia Lim; Ralph Higgins; Alessandra Martins; Ivan Goldberg; Colin I Clement

doi:10.5005/jp-journals-10008-1213

Incidence of Intraocular Pressure Elevation following Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration

J Curr Glaucoma Pract. 2017 Jan-Apr;11(1):3-7. doi: 10.5005/jp-journals-10008-1213. Epub 2017 Jan 18.

Authors

Gustavo Msm Reis¹, John Grigg², Brian Chua³, Anne Lee³, Ridia Lim⁴, Ralph Higgins⁵, Alessandra Martins⁶, Ivan Goldberg⁷, Colin I Clement³

Affiliations

¹ Consultant, Glaucoma Unit, Sydney Eye Hospital, Sydney, New South Wales, Australia.
² Associate Professor, Glaucoma Unit, Sydney Eye Hospital, Sydney; Discipline of Ophthalmology, Central Clinical School, University of Sydney Sydney, New South Wales, Australia.
³ Clinical Lecturer and Staff Specialist, Glaucoma Unit, Sydney Eye Hospital, Sydney; Discipline of Ophthalmology, Central Clinical School, University of Sydney Sydney, New South Wales, Australia.
⁴ Clinical Lecturer and Visiting Medical OfficerGlaucoma Unit, Sydney Eye Hospital, Sydney; Discipline of Ophthalmology, Central Clinical School, University of Sydney Sydney, New South Wales, Australia.
⁵ Visiting Medical Officer, Glaucoma Unit, Sydney Eye Hospital, Sydney; Discipline of Ophthalmology, Central Clinical School, University of Sydney Sydney, New South Wales, Australia.
⁶ Consultant, Department of Ophthalmology, Moorfields Eye Hospital London, United Kingdom.
⁷ Clinical Associate Professor, Glaucoma Unit, Sydney Eye Hospital, Sydney; Discipline of Ophthalmology, Central Clinical School, University of Sydney Sydney, New South Wales, Australia.

Abstract

Aim: The aim of this article is to evaluate the rate of patients developing sustained elevated intraocular pressure (IOP) after ranibizumab (Lucentis) intravitreal (IVT) injections.

Design: This is a retrospective study.

Participants: Charts of 192 consecutive patients receiving Lucentis for age-related macular degeneration (AMD) were retrospectively reviewed.

Materials and methods: We enrolled patients with at least two IOP measurements between injections. Elevated IOP was defined as >21 mm Hg with an increase of at least 20% from baseline. Noninjected contralateral eyes of the same patient cohort were used as control.

Main outcome measures: Primary outcome was defined as elevated IOP. Secondary outcomes were presence and type of glaucoma, number of injections, and time to IOP elevation.

Results: Elevated IOP occurred at a significantly higher rate in eyes receiving IVT ranibizumab (7.47%; n = 9) compared with control (0.93%; n = 1). Patients with preexisting glaucoma or ocular hypertension (OHT) were more likely to develop elevated IOP after IVT ranibizumab injection.

Conclusion: Intravitreal ranibizumab injections are associated with sustained IOP elevation in some eyes.

How to cite this article: Reis GMSM, Grigg J, Chua B, Lee A, Lim R, Higgins R, Martins A, Goldberg I, Clement CI. The Incidence of Intraocular Pressure Elevation following Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration. J Curr Glaucoma Pract 2017;11(1):3-7.

Keywords: Age-related macular degeneration; Intraocular pressure; Ranibizumab..